Soligenix logo
Soligenix SNGX
$ 0.34 6.51%

Annual report 2025
added 03-31-2026

report update icon

Soligenix Financial Statements 2011-2026 | SNGX

Annual Financial Statements Soligenix

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

6.12 M 1.96 M 4.81 M 5.54 M 1.77 M 42.6 M 47.7 M 11.9 M 13.6 M 8.84 M 22.9 M 23.7 M 35.6 M 18.4 M 8.77 M

Shares

5.19 M 1.66 M 7.76 M 2.87 M 2.68 M 27.5 M 19.4 M 13.2 M 6.14 M 3.48 M 2.61 M 2.06 M 1.55 M 1.11 M 1.1 M

Historical Prices

1.18 1.18 0.62 1.93 0.66 1.28 1.45 0.86 2.22 2.25 11.3 9.8 18 6 6

Net Income

-11.1 M -8.27 M -6.14 M -13.8 M -12.6 M -17.7 M -9.36 M -8.9 M -7.15 M -3.25 M -7.83 M -6.71 M -10.1 M -4.16 M -2.38 M

Revenue

- 119 K 839 K 949 K 824 K 2.36 M 4.63 M 5.24 M 5.43 M 10.4 M 8.77 M 7.04 M 3.22 M 3.14 M 7.66 M

Cost of Revenue

- 119 K 742 K 551 K 729 K 1.82 M 3.57 M 4.6 M 4.31 M 8.43 M 6.88 M 5.31 M 2.54 M 2.59 M 2.11 M

Gross Profit

- - 97.3 K 398 K 95.6 K 538 K 1.06 M 644 K 1.12 M 2.02 M 1.89 M 1.73 M 680 K 552 K 5.55 M

Operating Income

-11.8 M -9.44 M -7.7 M -14.2 M -13.1 M -18.6 M -10.5 M -9.06 M -7.59 M -5.71 M -7.11 M -10.8 M -7.16 M -4.69 M -2.96 M

Interest Expense

-11.7 K 550 K 43.2 K 5.92 K 30.8 K 61.1 K 149 K - - 2.22 K -8.02 K 1.31 K - - -

EBITDA

-11.8 M -9.44 M -7.7 M -14.2 M -13.1 M -18.5 M -10.5 M -9.01 M -7.53 M -5.62 M -6.86 M -6.52 M -6.93 M -4.46 M -2.73 M

Operating Expenses

11.8 M 9.44 M 7.8 M 14.6 M 13.2 M 19.1 M 11.6 M 9.7 M 8.72 M 7.72 M 9 M 8.49 M 7.84 M 5.24 M 8.51 M

General and Administrative Expenses

4.36 M 4.22 M 4.48 M 6.69 M 5.01 M 3.98 M 3.48 M 2.95 M 3.21 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Soligenix

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

4.33 M 3.28 M 3.05 M 2.51 M 2.2 M 1.26 M 658 K 649 K 649 K 453 K 2.91 M 2.91 M 2.87 M 2.87 M 2.86 M 42.9 M 40.7 M 40.1 M 36.8 M 30.6 M 29.6 M 26.9 M 23.4 M 21.8 M 20.1 M 18.4 M 18.1 M 17.7 M 17.5 M 8.74 M 8.73 M 8.73 M 5.76 M 5.6 M 5.47 M 5.47 M 3.43 M 3.18 M 3.13 M 3.13 M 2.65 M 25.7 M 24.4 M 23.9 M 20.7 M 19.9 M 19.7 M 19.6 M 19 M 12.3 M 11.2 M 11.2 M 11.1 M 11.1 M 11.1 M 11.1 M 11 M 10.9 M 11.1 M

Net Income

-2.53 M -2.7 M -3.24 M - -1.72 M -1.64 M -1.92 M - -1.66 M -1.61 M -1.05 M - -3.31 M -2.39 M -4.35 M - -3.59 M -1.9 M -2.36 M - -1.79 M -2.78 M -7.58 M - -2.72 M -2.12 M -1.64 M - -1.86 M -1.56 M -2.38 M - -963 K -2.31 M -1.73 M - -1.67 M -92.8 K -1.15 M - 2.77 M -3.98 M -4.57 M - -4.35 M -949 K -3.33 M - -6.56 M -3.41 M -1.09 M - -759 K -980 K -1.44 M - 2.2 M -1.93 M -1.72 M

Revenue

- - - - - 2.34 K 117 K - 130 K 207 K 257 K - 166 K 229 K 188 K - 186 K 215 K 148 K - 609 K 505 K 925 K - 1.25 M 1.54 M 1.14 M - 1.38 M 1.73 M 1.12 M - 1.82 M 991 K 1.33 M - 2.96 M 3.16 M 2.63 M - 3.88 M 1.1 M 816 K - 2.79 M 1.42 M 911 K - 312 K 632 K 900 K - 932 K - - - 5.8 M 406 K -

Cost of Revenue

- - - - - 2.34 K 117 K - 110 K 184 K 226 K - 129 K 193 K 92.2 K - 166 K 204 K 122 K - 387 K 363 K 830 K - 965 K 1.09 M 928 K - 1.24 M 1.49 M 979 K - 1.47 M 677 K 1.09 M - 2.63 M 2.34 M 2.23 M - 3.05 M 817 K 527 K - 2.11 M 1.03 M 629 K - 246 K 528 K 744 K - 762 K 616 K 557 K - 655 K 350 K 554 K

Gross Profit

- - - - - - - - 20 K 22.9 K 31.1 K - 36.7 K 35.3 K 95.8 K - 19.9 K 10.5 K 25.2 K - 222 K 142 K 95 K - 289 K 458 K 217 K - 144 K 232 K 141 K - 348 K 314 K 244 K - 329 K 818 K 399 K - 829 K 283 K 289 K - 678 K 384 K 282 K - 66.6 K 104 K 157 K - 170 K 147 K 90.8 K - 5.14 M 56.3 K 254 K

Operating Income

-2.58 M -2.76 M -3.31 M - -1.87 M -1.74 M -2.12 M - -1.78 M -1.63 M -2.15 M - -3.08 M -3.4 M -4.19 M - -3.36 M -2.99 M -2.23 M - -1.81 M -2.81 M -8.47 M - -2.77 M -2.16 M -2.3 M - -1.92 M -1.59 M -2.39 M - -970 K -2.32 M -1.74 M - -1.5 M -1.01 M -1.91 M - -1.27 M -2.03 M -1.56 M - -5.14 M -1.7 M -1.59 M - -1.86 M -2.76 M -1.09 M - -760 K -982 K -1.44 M - 2.2 M -1.93 M -1.72 M

Interest Expense

-2.82 K -7.92 K -788 - 67 K 64.2 K 173 K - - 2.35 K 40.9 K - - - -146 K - 30.8 K -215 K -129 K - 486 2.02 K 21.9 K - - - - - - - - - -789 5.23 K 4.75 K - 391 K 1.26 K -3.88 K - -3.73 K 551 561 - 428 322 291 - 652 - - - - - - - - - -

EBITDA

- - - - - - - - - - - - -3.08 M -3.4 M -4.18 M - -3.36 M -2.98 M -2.22 M - -1.8 M -2.8 M -8.46 M - -2.75 M -2.15 M -2.29 M - -1.91 M -1.58 M -2.38 M - -952 K -2.3 M -1.72 M - -1.48 M -987 K -1.88 M - -1.21 M -1.97 M -1.5 M - -5.08 M -1.64 M -1.53 M - -1.8 M -2.7 M -1.03 M - -696 K -930 K -1.38 M - 2.26 M -1.88 M -1.67 M

Operating Expenses

2.58 M 2.76 M 3.31 M - 1.87 M 1.74 M 2.12 M - 1.8 M 1.65 M 2.18 M - 3.12 M 3.43 M 4.29 M - 3.38 M 3 M 2.26 M - 2.03 M 2.96 M 8.57 M - 3.06 M 2.62 M 2.52 M - 2.06 M 1.82 M 2.53 M - 1.32 M 2.63 M 1.98 M - 1.83 M 1.83 M 2.3 M - 2.1 M 2.32 M 1.85 M - 5.82 M 2.08 M 1.87 M - 1.93 M 2.86 M 1.24 M - 930 K 1.13 M 1.53 M - 2.94 M 1.99 M 1.98 M

General and Administrative Expenses

997 K 1.09 M 1.08 M - 897 K 1.24 M 1.02 M - 973 K 891 K 1.24 M - 1.33 M 1.38 M 2.54 M - 1.15 M 1.06 M 949 K - 768 K 786 K 869 K - 789 K 769 K 874 K - 668 K 651 K 732 K - 712 K 847 K 764 K - 651 K 1 M 876 K - 840 K 875 K 817 K - 730 K 866 K 841 K - 711 K 720 K 488 K - 559 K 627 K 655 K - 595 K 25.2 K 604 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Soligenix SNGX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Soligenix plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 0.39 % $ 651 M usaUSA
Exelixis Exelixis
EXEL
$ 45.86 3.23 % $ 12.5 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.51 2.03 % $ 70 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.95 1.97 % $ 2.69 B belgiumBelgium
Genmab A/S Genmab A/S
GMAB
$ 27.7 0.59 % $ 17.1 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.37 1.2 % $ 6.83 B spainSpain
Genprex Genprex
GNPX
$ 0.9 1.28 % $ 839 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 94.84 -0.69 % $ 27.2 B germanyGermany
InflaRx N.V. InflaRx N.V.
IFRX
$ 2.44 24.11 % $ 152 M germanyGermany
Immuron Limited Immuron Limited
IMRN
$ 0.81 2.15 % $ 6.7 M australiaAustralia
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 76.26 1.34 % $ 12.2 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.25 0.49 % $ 260 M israelIsrael
INmune Bio INmune Bio
INMB
$ 1.55 0.65 % $ 38.4 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 85.73 3.65 % $ 7.24 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 12.98 -3.49 % $ 1.72 B australiaAustralia
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.93 2.6 % $ 3.8 B usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 42.33 5.48 % $ 3.64 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.55 1.43 % $ 5.84 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 107.42 1.52 % $ 5.39 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 4.01 40.03 % $ 1.23 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.48 0.26 % $ 2.99 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 41.5 19.36 % $ 286 B franceFrance
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA